CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina.
Transplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cfDNA in clinical practice, and emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx’s molecular testing services for xenotransplantation surveillance.
“As the transplant innovation leader, CareDx is thrilled to expand its presence globally with data from over 25 abstracts being presented at this internationally renowned TTS congress,” said Reg Seeto, CEO and President of CareDx. “We also look forward to sharing information about the next wave of innovation focused on the latest AiKidney™ and AiCAV™ developments.”
Dr. Alexandre Loupy, Paris Transplant Group, added, “I look forward to attending the meeting and discussing how artificial intelligence is transforming patient care by helping physicians tailor plans based on a patient’s risk profile for rejection and post-transplant complications.”
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading participation in the 29th International Congress of The Transplantation Society (the “TTS Congress”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its participation in the TTS Congress; risks that the TTS Congress fail to take place at the time and place shown in this press release; risks that the presented data at the TTS Congress do not match the statements contained in this press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005357/en/
Contact information
CareDx. Inc.
Media Relations
Anna Czene
(818)731-2203
aczene@caredx.com
Investor Relations
Ian Cooney
(415) 722-4563
investor@CareDx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Choicely: Eurovision Song Contest Built Their New Mobile App With a No Code Platform: “Incredible Flexibility”2.5.2024 09:00:00 EEST | Press release
The Eurovision Song Contest (ESC), the world’s largest live music event, has renewed their mobile app in time for this year’s event in Malmö, Sweden. The app was built using Choicely’s no code app platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501446902/en/ Eurovision Song Contest built their new mobile app with a no code platform. The app was built using Choicely’s no code app platform. The Eurovision app boasts an extensive news feed and media portal, and engagement tools full of interactive fan activations like the Scoreboard. With it, viewers can establish their own classic Eurovision ranking from 12 points on, and share the ranking on social media. (Graphic: Business Wire) “We were looking for a specialized partner who enables us to develop our app with speed and flexibility, so we can better serve the Eurovision fans across the globe,“ says Dave Goodman, ESC Digital and Communications Manager for Contest o
ESI Group Collaborates with Aberdeen Strategy and Research to Unveil "Shift Left" Insights on Virtual Prototyping2.5.2024 09:00:00 EEST | Press release
Regulatory News: ESI Group (Paris:ESI) has partnered with industry analysts Aberdeen Strategy and Research to present novel insights into the benefits of virtual prototyping for digital transformation in product development. The result of this collaboration is "Shift Left: The Value of Virtual Prototyping for Digital Transformation of the Product Development Lifecycle," an in-depth examination of how virtual prototyping can revolutionize industries such as automotive, aerospace, and heavy machinery. The research found that top-performing organizations embracing 'shift left’ - an early-stage digital approach to product performance testing - were able to significantly reduce their reliance on physical prototypes by 75.6% and decrease engineering change orders by 73.8%, resulting in a 75.2% decrease in the overall development time. The research also explores the key challenges to a successful deployment and details the “Top 10” long-term benefits realized by organizations that adopt a sol
Infobip and Nokia Partner to Enable Developers to Build Wider Array of Telco Network Powered Applications Faster2.5.2024 08:00:00 EEST | Press release
Infobip, the global cloud communications platform, and Nokia today announced a partnering agreement that will enable the global developer community to leverage both companies’ Application Programmable Interface (API) platforms in order to build a wider array of telco network powered applications faster for consumer, enterprise, and industrial customers. Infobip’s market-leading cloud Communications Platform as a Service (CPaaS) provides developers with APIs for integrating real-time omnichannel communications features such as SMS, voice, video, chat apps, and network APIs into their applications. Nokia’s Network as Code platform with developer portal offers developers APIs for tapping into 5G network capabilities like quality of service (QoS) on demand, device location precision and network slicing, as well as 4G capabilities. Developers will be able to utilize all of those capabilities more easily, giving them complete coverage of Network and CPaaS APIs in the development of new use c
IFF Declares Dividend for Second Quarter 20241.5.2024 23:15:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240501801418/en/ Contact information Media Relations: Paulina Heinkel 332.877.5339 Media.request@iff.com Investor Rel
Qualcomm Earnings Release Available on Company’s Investor Relations Website1.5.2024 23:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced the Company’s financial results for its second quarter of fiscal 2024 through an earnings release that is available on the Qualcomm Investor Relations website at http://investor.qualcomm.com/results.cfm. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K and will be available on the SEC website at http://www.sec.gov. As previously announced, Qualcomm will host a conference call to discuss its fiscal second quarter results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at http://investor.qualcomm.com/events.cfm. An audio replay will be available at http://investor.qualcomm.com/events.cfm and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use reservation number 13745532. About Qualcomm Qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom